Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONACO: Vancomycin + Piperacillin-Tazobactam vs Vancomycin + Cefepime for Infection
NCT06954129Phase 4Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jan 2026
- Primary completion
- May 2029
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in bacterial infection comparing Vancomycin + Piperacillin-Tazobactam with Vancomycin + Cefepime (2 arms). Primary endpoint: Serum Cystatin C Concentration at 5 days. Started Jan 2026; status: recruiting.
02
Drugs
piperacillin + tazobactamcefepime
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT06954129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954129.